<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471718</url>
  </required_header>
  <id_info>
    <org_study_id>VICC URO 0426</org_study_id>
    <secondary_id>VU-VICC-URO-0426</secondary_id>
    <nct_id>NCT00471718</nct_id>
  </id_info>
  <brief_title>ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy</brief_title>
  <official_title>A Phase1/2 Trial of ABT-751 in Patients With Advanced, Androgen-Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop the
      growth of tumor cells, either by killing the cells or by stopping them from dividing.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of ABT-751 and to
      see how well it works in treating patients with metastatic prostate cancer that did not
      respond to hormone therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the safety and efficacy of ABT-751 in patients with androgen-independent,
           hormone-refractory metastatic prostate cancer and determine the maximum tolerated dose
           (MTD) and optimal phase II dose of this drug in these patients.

      Secondary

        -  Determine the objective response rate (partial and complete response) in patients with
           measurable disease treated with this drug.

        -  Evaluate the effect of this drug on prostate-specific antigen (PSA) response in patients
           with nonmeasurable disease.

        -  Determine the time to tumor progression in patients treated with this drug.

        -  Determine survival of patients treated with this drug.

        -  Determine the toxicity of this drug in these patients.

      OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

        -  Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21. Treatment
           repeats every 28 days in the absence of disease progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses of ABT-751 until the maximum tolerated dose
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6
      patients experience dose-limiting toxicity. Up to 50 additional patients may be treated at
      the recommended phase II dose (RPTD) which is the dose level at the maximally administered
      dose.

        -  Phase II: Patients receive ABT-751 at the MTD determined in phase I. After completion of
           study treatment, patients are followed every 3 months for 2 years.

      PROJECTED ACCRUAL: A total of 53 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    pharmaceutical company closed study because the treatment was not effective
  </why_stopped>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>up to four weeks</time_frame>
    <description>MTD is determined by the 3+3 study design, in which patients are enrolled in cohorts of 3. In any dose cohort, if 1 patient of 3 experience dose-limiting toxicity (DLT), three additional patients will be enrolled at the same dose level. Whenever &gt;=2 of 6 subjects experience a DLT, then the maximum tolerated dose (MTD) has been exceeded. The MTD is generally one dose below that at which DLT occurs in &gt;= 2 of 6 subjects in any given cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Who Demonstrated Treatment Effectiveness Based on Prostate Specific Antigen (PSA) Response in Non-measurable Disease</measure>
    <time_frame>after four weeks</time_frame>
    <description>Patients with a minimum 50% decline in PSA from pre-treatment baseline, confirmed by a second PSA 4 or more weeks later, measured in nanograms per milliliter of blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Objective Response (CR &amp; PR) by RECIST</measure>
    <time_frame>after four weeks</time_frame>
    <description>Number of participants in each best tumor response category, RECIST criteria (v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) &gt; 30% decrease in sum longest diameter (LD) of target lesions, progressive disease (PD) &gt; 20% increase in sum LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of smallest sum of the LD of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Tumor Progression</measure>
    <time_frame>date on study to date of progression</time_frame>
    <description>Number of weeks from the date the patient started study drug to the date of the patient's tumor progression documented radiographically or by PSA testing.
Tumor progression is measured at baseline and after two 28-day cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>date on study to date of death from any cause</time_frame>
    <description>Number of weeks from the date the patient started study drug to the date of the patient's death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile Based on Number of Patients With Worst Grade Toxicities</measure>
    <time_frame>at 30 days after final treatment dose</time_frame>
    <description>Not all participants necessarily have an adverse event, thus not everyone will be accounted for in worst-grade toxicities. Likewise, one participant can potentially have more than one event in various grades 1-5 which accounts for the difference in number of patients analyzed and total number in the worst-grade toxicity tables. Tables represent the number of patients with worst-grade toxicity at each of five grades (grade 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening or disabling, grade 5 = death)following NCI Common Toxicity Criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I/II: Chemotherapy ABT-751</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21.
Phase II: Patients receive ABT-751 twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-751</intervention_name>
    <description>Phase I:
Cohort | Number of Patients |Dose (mg) ABT-751 (BID)
-1 | 3-6 |100 mg BID
1 | 3-6 |125 mg BID
2 | 3-6 |150 mg BID
3 | 3-6 |175 mg BID
4 | 3-6 |200 mg BID
Phase II:
Patients receive ABT-751 at 125mg po BID for 7 days on, 7 days off (X2) for a 28 day cycle</description>
    <arm_group_label>Phase I/II: Chemotherapy ABT-751</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients at least 18 years of age.

          -  Patients must have histologically proven adenocarcinoma of the prostate gland.

          -  Patients must have metastatic disease (e.g. bone metastases, pelvic mass, nodal, liver
             or lung metastases), with evidence of radiographic progression (including bone scans
             observed during last treatment) or serologically -Patients with bone-only metastases
             (i.e. lacking soft tissue or visceral disease) must have a PSA level &gt; 10 ng/mls.
             Patients with soft tissue metastases and/or visceral disease must have either
             measurable disease OR a PSA level &gt; 10 ng/ml.

          -  Patients must have had prior treatment with bilateral orchiectomy or other primary
             hormonal therapy (e.g. LHRH therapy, estrogens, etc.) with evidence of treatment
             failure and simultaneous documentation of a castrate testosterone level (&lt; 50 ng/dL)
             NOTE: Patients who have not undergone bilateral orchiectomy must continue LHRH agonist
             therapy for the duration of this protocol unless this medically contraindicated.

          -  For patients previously treated with flutamide, nilutamide, or bicalutamide: patients
             must have discontinued flutamide or nilutamide &gt; 4 weeks prior to randomization (&gt; 6
             weeks for bicalutamide) with no evidence of an anti-androgen withdrawal response (i.e.
             no decline in serum PSA and/or no improvement in baseline scans).

          -  Patients must have received prior therapy with docetaxel alone or in combination with
             either prednisone or estramustine. This therapy may have been given in a neoadjuvant,
             adjuvant or metastatic setting

          -  Patients must not have received radiotherapy &lt; 3 weeks prior to randomization. If
             patients have received prior radiotherapy to an evaluable lesion(s), there must be
             evidence of radiographic progression prior to entry.

          -  Patients must not have received prior Strontium 89, Samarium 153, or other therapeutic
             radioisotopes.

          -  Patients must have recovered from all systemic toxicities due to prior treatment for
             prostate cancer (does not include incontinence, impotence, etc. secondary to primary
             therapy)

          -  The patient must have an ECOG Performance Status of 0-1

          -  The patient must have adequate hematologic, renal and hepatic function as follows:

               1. Hematologic: ANC &gt; 1200/mm3; hemoglobin &gt; 9.0 g/dl; platelets &gt; 100,000/mm3

               2. Renal: serum creatinine &lt; 2.0 mg/dL

               3. Hepatic: bilirubin &lt; 2.5 mg/dL; AST and ALT &lt; 2.5X upper limit of normal (ULN); &lt;
                  5X ULN for patients with hepatic metastases

          -  Sexually-active patients must use a contraceptive method deemed acceptable by the
             investigator while in the study and for up to 3 months following completion of
             therapy.

          -  The patient or the patient's legally acceptable representative has voluntarily signed
             and dated an informed consent approved by and Institutional Review Board prior to any
             study any study specific procedures.

          -  Patients may be receiving bisphosphonate therapy prior to randomization and continue
             while receiving protocol therapy, but must not begin treatment with bispohosphonates
             while receiving protocol therapy. Patients on bisphosphonates must have completed at
             least 4 weeks of bisphosphonate therapy prior to entry onto study.

          -  Patients with a history of a prior malignancy are eligible provided they were treated
             with curative intent and have been free of disease for the time period considered
             appropriate for the specific malignancy.

        Exclusion Criteria:

          -  No active angina pectoris, uncontrolled hypertension, or known heart disease of New
             York Heart Association Class III-IV. Patients must not have a history of myocardial
             infarction, congestive cardiac failure (New York Heart Association Class 3), or
             coronary angioplasty/stenting &lt; 6 months prior to entry.

          -  No carcinomatous meningitis or brain metastases.

          -  Any investigational therapy within 4 weeks.

          -  No serious concurrent medical illness or active infection, which, in the opinion of
             the investigator, would jeopardize the ability of the patient to receive the
             chemotherapy outlined in this protocol with reasonable safety.

          -  Documented history of allergy to sulfa medications.

          -  Current colchicines treatment

          -  Greater than Grade 1 CTC neurology category findings (Appendix A).

          -  Prior treatment with more than 1 prior chemotherapy regimen.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Sosman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2007</study_first_submitted>
  <study_first_submitted_qc>May 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <results_first_submitted>October 26, 2011</results_first_submitted>
  <results_first_submitted_qc>May 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2012</results_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Jeffrey A. Sosman, MD</investigator_full_name>
    <investigator_title>Professor of Medicine; Director, Melanoma and Tumor Immunotherapy</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study began enrolling October 2004 through December 2007.</recruitment_details>
      <pre_assignment_details>A total of 34 patients were consented in Phase I and Phase II, 7 of which were not eligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I/II: ABT-751</title>
          <description>Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21. Phase II: Patients receive ABT-751 at 125mg twice daily, 7 days on, 7 days off (x2)for a 28-day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other complicating disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>disease progression</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I/II: ABT-751</title>
          <description>Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21. Phase II: Patients receive ABT-751 at 125mg twice daily, 7 days on, 7 days off (x2)for a 28-day cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>MTD is determined by the 3+3 study design, in which patients are enrolled in cohorts of 3. In any dose cohort, if 1 patient of 3 experience dose-limiting toxicity (DLT), three additional patients will be enrolled at the same dose level. Whenever &gt;=2 of 6 subjects experience a DLT, then the maximum tolerated dose (MTD) has been exceeded. The MTD is generally one dose below that at which DLT occurs in &gt;= 2 of 6 subjects in any given cohort.</description>
        <time_frame>up to four weeks</time_frame>
        <population>Phase I patients who received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-751</title>
            <description>Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21. Phase II: Patients receive ABT-751 at 125mg twice daily, 7 days on, 7 days off (x2)for a 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>MTD is determined by the 3+3 study design, in which patients are enrolled in cohorts of 3. In any dose cohort, if 1 patient of 3 experience dose-limiting toxicity (DLT), three additional patients will be enrolled at the same dose level. Whenever &gt;=2 of 6 subjects experience a DLT, then the maximum tolerated dose (MTD) has been exceeded. The MTD is generally one dose below that at which DLT occurs in &gt;= 2 of 6 subjects in any given cohort.</description>
          <population>Phase I patients who received treatment</population>
          <units>mg twice a day</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Objective Response (CR &amp; PR) by RECIST</title>
        <description>Number of participants in each best tumor response category, RECIST criteria (v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) &gt; 30% decrease in sum longest diameter (LD) of target lesions, progressive disease (PD) &gt; 20% increase in sum LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of smallest sum of the LD of target lesions.</description>
        <time_frame>after four weeks</time_frame>
        <population>Participants with measurable disease who completed at least one cycle of treatment with tumor assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I/11: ABT-751</title>
            <description>Duration of overall response from time measurements are met for CR or PR until date that recurrence or PD is objectively documented</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Objective Response (CR &amp; PR) by RECIST</title>
          <description>Number of participants in each best tumor response category, RECIST criteria (v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) &gt; 30% decrease in sum longest diameter (LD) of target lesions, progressive disease (PD) &gt; 20% increase in sum LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of smallest sum of the LD of target lesions.</description>
          <population>Participants with measurable disease who completed at least one cycle of treatment with tumor assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Tumor Progression</title>
        <description>Number of weeks from the date the patient started study drug to the date of the patient's tumor progression documented radiographically or by PSA testing.
Tumor progression is measured at baseline and after two 28-day cycles</description>
        <time_frame>date on study to date of progression</time_frame>
        <population>Patients who received treatment and who were available for measurement of tumor or who available for PSA testing</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I/II: ABT-751</title>
            <description>Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21. Phase II: Patients receive ABT-751 at 125mg twice daily, 7 days on, 7 days off (x2)for a 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Tumor Progression</title>
          <description>Number of weeks from the date the patient started study drug to the date of the patient's tumor progression documented radiographically or by PSA testing.
Tumor progression is measured at baseline and after two 28-day cycles</description>
          <population>Patients who received treatment and who were available for measurement of tumor or who available for PSA testing</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3.83" upper_limit="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Number of weeks from the date the patient started study drug to the date of the patient's death.</description>
        <time_frame>date on study to date of death from any cause</time_frame>
        <population>At the time of this analysis, all 27 patients were deceased due to progressive prostate cancer.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I/II: ABT-751</title>
            <description>Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21. Phase II: Patients receive ABT-751 at 125mg twice daily, 7 days on, 7 days off (x2)for a 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Number of weeks from the date the patient started study drug to the date of the patient's death.</description>
          <population>At the time of this analysis, all 27 patients were deceased due to progressive prostate cancer.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" lower_limit="26.4" upper_limit="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Profile Based on Number of Patients With Worst Grade Toxicities</title>
        <description>Not all participants necessarily have an adverse event, thus not everyone will be accounted for in worst-grade toxicities. Likewise, one participant can potentially have more than one event in various grades 1-5 which accounts for the difference in number of patients analyzed and total number in the worst-grade toxicity tables. Tables represent the number of patients with worst-grade toxicity at each of five grades (grade 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening or disabling, grade 5 = death)following NCI Common Toxicity Criteria</description>
        <time_frame>at 30 days after final treatment dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I/II: ABT-751</title>
            <description>Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21. Phase II: Patients receive ABT-751 at 125mg twice daily, 7 days on, 7 days off (x2)for a 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Profile Based on Number of Patients With Worst Grade Toxicities</title>
          <description>Not all participants necessarily have an adverse event, thus not everyone will be accounted for in worst-grade toxicities. Likewise, one participant can potentially have more than one event in various grades 1-5 which accounts for the difference in number of patients analyzed and total number in the worst-grade toxicity tables. Tables represent the number of patients with worst-grade toxicity at each of five grades (grade 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening or disabling, grade 5 = death)following NCI Common Toxicity Criteria</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No. of patients with worst-grade toxicity of 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of patients with worst-grade toxicity of 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of patients with worst-grade toxicity of 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of patients with worst-grade toxicity of 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of patients with worst-grade toxicity of 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Demonstrated Treatment Effectiveness Based on Prostate Specific Antigen (PSA) Response in Non-measurable Disease</title>
        <description>Patients with a minimum 50% decline in PSA from pre-treatment baseline, confirmed by a second PSA 4 or more weeks later, measured in nanograms per milliliter of blood.</description>
        <time_frame>after four weeks</time_frame>
        <population>Men with non-measurable disease: all other lesions, bone lesions, leptomeningeal disease, cystic lesions, abdominal masses that are not followed by imaging techniques</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I/11: ABT-751</title>
            <description>Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21. Phase II: Patients receive ABT-751 at 125mg twice daily, 7 days on, 7 days off (x2)for a 28-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Demonstrated Treatment Effectiveness Based on Prostate Specific Antigen (PSA) Response in Non-measurable Disease</title>
          <description>Patients with a minimum 50% decline in PSA from pre-treatment baseline, confirmed by a second PSA 4 or more weeks later, measured in nanograms per milliliter of blood.</description>
          <population>Men with non-measurable disease: all other lesions, bone lesions, leptomeningeal disease, cystic lesions, abdominal masses that are not followed by imaging techniques</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phase I/II: ABT-751</title>
          <description>Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21. Phase II: Patients receive ABT-751 at 125mg twice daily, 7 days on, 7 days off (x2)for a 28-day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hemoglobin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>extremity pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>pain, tumor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neuropathy cranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>neuropathy motor weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>speech impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>extrapyramidal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>mood alteration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal disorders</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>xerostomia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="26" subjects_affected="15" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="36" subjects_affected="18" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="35" subjects_affected="19" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alkaline phosphatase increase</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>hyperuricemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>elevated transaminases</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neuropathy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>urine retention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>sweats</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeff Sosman, MD</name_or_title>
      <organization>Vanderbilt-Ingram Cancer Center</organization>
      <phone>615-936-3048</phone>
      <email>jeff.sosman@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

